Health

Max Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.

About its animal-health unit Elanco, Eli Lilly & Co. protested too much. 

The drugmaker has repeatedly claimed Elanco was a core part of its business, rebuffing investor calls for a divestiture. But on Tuesday, along with its third-quarter earnings results, Lilly announced it will decide whether to spin off, sell, or keep the unit by mid-2018.

Lilly said the business has grown to the point where it can stand alone and that it wants to "maximize future value." But this change in attitude may also be motivated by a variety of pressures on Lilly's business and share price. 

Bad Review
Lilly's shares dropped on Tuesday as it announced a long anticipated potential sale of its Elanco animal health unit
Source: Bloomberg

For one, the company likely feels some pressure to live up to its valuation. It trades at a premium to other large U.S. pharmaceutical companies.

Premium Blend
Lilly trades at a significant premium to its U.S. based large pharma peers
Source: Bloomberg

Spinning off or selling Elanco could help by focusing attention on Lilly's more rapidly growing pharmaceutical unit. Elanco's momentum has noticeably waned recently and could weigh on Lilly's earnings growth. 

Reversal of Fortune
Eli Lilly's human pharma business has pretty clearly outperformed its animal health unit recently

Lilly has also made cost containment and margin expansion a key part of its growth story; its operating margins are low compared to other large U.S. pharma companies. The company has already announced major job cuts, and splitting from Elanco could be another boost.  

Back of the Pack
Lilly is already slashing jobs to boost its margins -- cutting Elanco loose may help as well
Source: Bloomberg
*most recent quarter of data available

Most importantly, the move could generate billions in cash to invest in the pharma business. The unit is growing, but faces a number of risks. Lilly said on its earnings call that it won't challenge a Sanofi copy of its best-selling medicine, Humalog. Sanofi's competing drug may lead to significant sales and pricing pressure. 

Two other diabetes drugs, Jardiance and Trulicity, are expected to provide the bulk of Lilly's growth over the next few years. But they will face competition from rival medicines, as well as a general pricing pressure afflicting diabetes drugs.

Lilly's most significant recent launches, Taltz and Verzenio, will both have to fight for share in highly competitive markets. A number of its older medicines are set to face increasing generic competition.

Lilly has the cash and debt capacity to make some deals. But the proceeds from an Elanco sale or IPO would widen its M&A aperture substantially

The fact that Lilly's shares fell more than 3 percent in spite of this long-anticipated announcement is telling. But don't read it as a negative review of the move itself -- it's more likely a reaction to the challenges that may be inspiring it. 

This column does not necessarily reflect the opinion of Bloomberg LP and its owners.

To contact the author of this story:
Max Nisen in New York at mnisen@bloomberg.net

To contact the editor responsible for this story:
Mark Gongloff at mgongloff1@bloomberg.net